Keywords: Novartis, Financial results, Third-quarter 2012
Novartis sales in third-quarter 2012 disappoint; EPS in line
Article | 25 October 2012
Swiss drug major Novartis (NOVN: VX) reported third-quarter 2012, showing that net sales reached $13.8 billion (-7%, -2% at constant exchange), arguing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
